Ahrens U, Kaden V, Drexler C, Visser N
Federal Research Centre for Virus Diseases of Animals, Friedrich-Loeffler-Institutes, Institute of Infectology, Boddenblick 5a, D-17498, Insel Riems, Germany.
Vet Microbiol. 2000 Nov 15;77(1-2):83-97. doi: 10.1016/s0378-1135(00)00265-0.
The efficacy of the classical swine fever (CSF) subunit marker vaccine Porcilis Pesti based on baculovirus expressed envelope glycoprotein E2 of CSF virus (CSFV) was evaluated in pregnant sows. Ten gilts were vaccinated with one dose of marker vaccine, followed by a second dose 4 weeks later. Four gilts remained unvaccinated and received a placebo at the same times. Thirty-three days after the second vaccination all animals were artificially inseminated. Neither local or systemic reactions nor an increase of body temperature were observed after vaccinations. All gilts showed a normal course of pregnancy. Thirty-five days after first vaccination all animals developed E2 specific neutralising antibodies with titres in the range of 5.0 and 7.5 log(2). No antibodies to CSFV-E(rns) were found in ELISA. On day 65 of gestation (126 days after the first immunisation) all sows were infected intranasally using 2ml (10(6.6) TCID(50)/ml) of the low virulent CSFV strain "Glentorf". After challenge in two of the unvaccinated control sows a slight transient increase of body temperature was observed, whereas leukopenia was demonstrated in all control animals. In addition all controls became viraemic. Vaccinations with the CSFV subunit vaccine protected the animals from clinical symptoms of CSF. In two sows a moderate decrease of leukocyte counts was detected on day 5 post infection. In contrast to the unvaccinated control sows in none of the vaccinated animals virus was isolated from the nasal swabs or the blood. Approximately 40 days after challenge all sows were killed and necropsy was done. The sows and their offspring were examined for the presence of CSFV in blood, bone marrow and different organs. No virus was found in any of the sows. In contrast, in all litters of the control sows CSFV was found in the blood as well as in the organ samples. Nine out of 10 litters of the vaccinated sows were protected from CSFV infection. Blood samples, lymphatic organs and bone marrow of these animals were all virologically negative. When sera were tested for CSFV-antibodies all sows had developed E(rns)-specific antibodies but no CSFV-specific antibodies were found in any of the progeny. It was concluded that vaccination with CSF subunit marker vaccine Porcilis((R)) Pesti protected 90% of the litters from viral infection when sows were challenged mid-gestation using the CSFV-strain "Glentorf".
在怀孕母猪中评估了基于杆状病毒表达的猪瘟病毒(CSFV)包膜糖蛋白E2的经典猪瘟(CSF)亚单位标记疫苗Porcilis Pesti的效力。10头后备母猪接种一剂标记疫苗,4周后再接种第二剂。4头后备母猪未接种疫苗,同时接受安慰剂。第二次接种后33天,所有动物均进行人工授精。接种疫苗后未观察到局部或全身反应,也未出现体温升高。所有后备母猪的妊娠过程均正常。首次接种后35天,所有动物均产生了E2特异性中和抗体,效价在5.0至7.5 log(2)范围内。在ELISA中未发现针对CSFV-E(rns)的抗体。妊娠65天(首次免疫后126天),所有母猪经鼻内接种2ml(10(6.6) TCID(50)/ml)低毒力CSFV毒株“Glentorf”。攻毒后,2头未接种疫苗的对照母猪体温出现轻微短暂升高,而所有对照动物均出现白细胞减少。此外,所有对照动物均出现病毒血症。接种CSFV亚单位疫苗可使动物免受CSF临床症状的影响。感染后第5天,在2头母猪中检测到白细胞计数适度下降。与未接种疫苗的对照母猪不同,在任何接种疫苗的动物中均未从鼻拭子或血液中分离到病毒。攻毒后约40天,所有母猪均被处死并进行尸检。检查母猪及其后代的血液、骨髓和不同器官中是否存在CSFV。在任何母猪中均未发现病毒。相比之下,在所有对照母猪的仔猪中,血液和器官样本中均发现了CSFV。10头接种疫苗的母猪中有9头的仔猪免受CSFV感染。这些动物的血液样本、淋巴器官和骨髓在病毒学检测中均为阴性。当检测血清中的CSFV抗体时,所有母猪均产生了E(rns)特异性抗体,但在任何后代中均未发现CSFV特异性抗体。得出的结论是,当在妊娠中期使用CSFV毒株“Glentorf”对母猪进行攻毒时,接种CSF亚单位标记疫苗Porcilis((R)) Pesti可使90%的仔猪免受病毒感染。